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Abstract. Equatorial Guinea (EG) has implemented a successful malaria control program on Bioko Island. A highly
effective vaccine would be an ideal complement to this effort and could lead to halting transmission and eliminating
malaria. Sanaria® PfSPZ Vaccine (Plasmodium falciparum sporozoite Vaccine) is being developed for this purpose. To
begin the process of establishing the efﬁcacy of and implementing a PfSPZ Vaccinemass vaccination program in EG, we
decided to conduct a series of clinical trials of PfSPZ Vaccine on Bioko Island. Because no clinical trial had ever been
conducted in EG, we ﬁrst successfully established the ethical, regulatory, quality, and clinical foundation for conducting
trials.Wenow report the safety, tolerability, and immunogenicity results of the ﬁrst clinical trial in the history of the country.
Thirty adult males were randomized in the ratio 2:1 to receive three doses of 2.7 × 105 PfSPZ of PfSPZ Vaccine (N = 20) or
normal saline placebo (N = 10) by direct venous inoculation at 8-week intervals. The vaccine was safe and well tolerated.
Seventy percent, 65%, and 45% of vaccinees developed antibodies to Plasmodium falciparum (Pf ) circumsporozoite
protein (PfCSP) by enzyme-linked immunosorbent assay, PfSPZ by automated immunoﬂuorescence assay, and PfSPZ
by inhibition of sporozoite invasion assay, respectively. Antibody responses were signiﬁcantly lower than responses in
U.S. adults who received the same dosage regimen, but not signiﬁcantly different than responses in young adult Malians.
Basedon these results, a clinical trial enrolling 135 subjects aged 6months to 65 years has been initiated in EG; it includes
PfSPZ Vaccine and ﬁrst assessment in Africa of PfSPZ-CVac. ClinicalTrials.gov identiﬁer: NCT02418962.
INTRODUCTION
Malaria hasmajor public health signiﬁcance in sub-Saharan
Africa.1 World Health Organization-Global Technical Strategy
has set a goal of eliminating malaria from at least 10 malaria-
endemic countries by the year 2020.2 Development and de-
ployment of new tools such as highly efﬁcacious malaria
vaccines that can interrupt malaria transmission will be es-
sential to achieve this goal. The RTS,S/AS01 candidate
malaria vaccine has shown moderate efﬁcacy against clinical
disease in young children,3 but its limited efﬁcacy against in-
fection and signiﬁcant adverse events (AEs) restrict its use-
fulness for malaria elimination.4,5
Sanaria® PfSPZ Vaccine is a live attenuated Plasmodium
falciparum (Pf ) whole sporozoite (SPZ) vaccine that is cur-
rently being assessed in clinical trials in the United States,
Europe, and Africa. PfSPZ Vaccine has been well tolerated,
safe, and protective against controlled human malaria in-
fection (CHMI) in the United States and against natural ex-
posure to malaria in Mali.6,7 Protection durable for at least
6–14 months has been demonstrated.7–10
A robust malaria control program has been in place on Bioko
Island, Equatorial Guinea (EG) since 2004.11 Using insecticide-
treated bed nets, indoor residual spraying and early diagnosis
and treatment with artemisinin combination therapy,11 the Bioko
Island Malaria Control Program has reduced the average prev-
alence of malaria parasitaemia in the island’s children from 45%
in 2000 to 11.1% in 2016. To capitalize on this success, the EG
Malaria Vaccine Initiative (EGMVI) was established in 2014 to as-
sess the utility of PfSPZ Vaccine to eliminate malaria. EGMVI is
funded by the Government of EG and three U.S. energy compa-
nies, Marathon EG Production Limited, Noble Energy, Atlantic
Methanol Production Company, and EG LNG, and aims to cul-
minate itsactivitieswithan island-widemassvaccinationprogram.
Here we report the ﬁndings from the ﬁrst clinical trial in the
history of EG. This was a phase 1 clinical trial to evaluate the
safety, tolerability, and immunogenicity of three doses of 2.7 ×
105 PfSPZ of PfSPZ Vaccine administered by direct venous
inoculation (DVI) to healthy, malaria-exposed semi-immune
young Equatoguinean men living in a malaria-endemic region
of Bioko Island, EG.
MATERIALS AND METHODS
Clinical trial design. The primary objective of this study
was to assess the safety, tolerability and immunogenicity of
three doses of 2.7 × 105PfSPZof PfSPZVaccine as compared
with normal saline (NS) placeboadministered to healthy young
EquatoguineanmenbyDVI at 8-week intervals. The studywas
conducted at La Paz Medical Center, Malabo, EG. A Safety
Monitoring Committee (SMC) was appointed by the study
sponsor and consisted of three external experts and the local
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Medical Center Drive, Rockville, MD 20850. E-mail: slhoffman@
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safety monitor, who was an independent Equatoguinean
physician based in Malabo and accessible during the entire
study period.
The study had three groups with a total of 33 volunteers.
Group 1, the sentinel safety group, included three volunteers
who received 1.35 × 105 PfSPZ followed by 2.7 × 105 PfSPZ of
PfSPZ Vaccine 2 weeks later. The SMC reviewed the data
from Group 1 and then recommended proceeding with vac-
cination of the rest of the volunteers.
For Groups 2 and 3, the study was a phase 1 randomized,
double-blind, placebo-controlled clinical trial. Twenty volun-
teers in Group 2 received three doses of 2.7 × 105 PfSPZ of
PfSPZ Vaccine and 10 volunteers in Group 3 received three
doses of NS at 8-week intervals.
Ethical considerations. Ethical approval was obtained
from the National Ethics Committee of EG, the Ifakara Health
Institute Institutional Review Board, Dar es Salaam, Tanzania,
the MaGil Institutional Review Board in Maryland, USA, and
the Ethical Review Committee of Northwestern and Central
Switzerland. The study was registered at ClinicalTrials.gov
(ClinicalTrials.gov registration number: NCT02418962). The
volunteers were briefed on the speciﬁcs of the planned study,
and then were assessed for their understanding of study
procedures using amultiple-choice questionnaire. Only those
who correctly answered all 10 questions proceeded with the
consenting procedure. All volunteers gave a written informed
consent before any study procedure was done. As EG is a
Spanish-speaking country, approved Spanish-translated in-
formed consent forms were used during the consenting pro-
cess, which was conducted by investigators who were ﬂuent
in Spanish.
Vaccine. PfSPZ Vaccine is composed of aseptic, puriﬁed,
metabolically active, nonreplicating (live, radiation attenu-
ated) cryopreserved PfSPZ.12,13 The vaccine is stored in liq-
uid nitrogen vapor phase at −150C to −196C. Before
administration, PfSPZ Vaccine is thawed and then diluted in
phosphate-buffered saline (PBS) with human serum albumin
to achieve the correct dose.
Study population and enrollment criteria. Volunteers
were healthy male adults between 18 and 35 years of age
recruited from the towns of Baney and Rebola located in
Baney District, Bioko Island. The study area has low malaria
endemicity with estimated prevalence in 2016 of less than 1%
in children aged 2 to 14 years. Volunteers were excluded from
enrollment if they were taking immunosuppressive drugs,
or had 1) clinically signiﬁcant acute or chronic diseases,
2) clinically signiﬁcant abnormalities in electrocardiogram at
screening, 3) plans to travel outside Bioko Island, EG, in the
ﬁrst 9 months of the study, 4) immunosuppressive disorders,
5) a positive blood test for hepatitis B surface antigen
(HBSAg), hepatitis C virus, or human immunodeﬁciency virus
(HIV )-1, or 6) clinically signiﬁcant abnormalities on basic
hematology, hepatic and renal function laboratory tests.
Volunteers with conﬁrmed malaria parasitemia by micros-
copy of Giemsa-stained thick blood smears (sensitivity of
2–4 parasites/μL blood), intestinal parasites by microscopy
of Lugol-stained fecal material (10× objective for detection
and quantiﬁcation and 40× objective for species identiﬁca-
tion), or urinary tract infections were treated and conﬁrmed
cured before they were enrolled into the study. In addition,
volunteers with risk factors for clinically active tuberculosis
plus a positive tuberculin skin test were excluded.
Randomization and vaccination. No randomization was
performed in Group 1 in which all volunteers received PfSPZ
Vaccine. Participants in Group 2 and 3 were randomized in a
ﬁnal ratio of 2:1 to receive threedosesof either 2.7×105PfSPZ
of PfSPZ Vaccine or NS. Randomization was done using a
computer-generated list of randomnumbersbyan independent
statistician from theSwissTropical andPublicHealth Institute.
At enrollment, volunteers were assigned either PfSPZ Vaccine
or NS as speciﬁed in a master randomization list.
PfSPZ Vaccine and NS were administered as a 0.5 mL
volume by DVI using a 1 mL syringe with a 25-gauge needle.
Syringe preparation was done in a biological safety cabi-
net in a pharmacy out of sight of the study physicians
and nurses who evaluated the study end points and of
the study volunteers. Pharmacy personnel preparing
the doses were aware of the treatment assignments, but
took no other part in study-related procedures and were
instructed not to reveal the assignments to either the vol-
unteers or study investigators. The study clinical team was
blinded to treatment.
Deﬁnitions. An AE was deﬁned as any unfavorable or
unintended change in body structure, body function or
laboratory result associated temporally with the study treat-
ment, whether or not it was considered to be related to
the study treatment. A serious AE (SAE) was deﬁned as any
untoward medical occurrence that resulted in death, was
life threatening, required hospitalization or prolongation of
hospitalization, resulted in disability, or was otherwise con-
sidered serious by the investigators. All AEs were classiﬁed
according to the preferred term in the Medical Dictionary for
Regulatory Activities (MedDRA). When the report ﬁled by the
investigator did not clearly correspond to aMedDRA term, the
most appropriate classiﬁcation was clariﬁed in discussion
between the study sponsor and the investigators before
unblinding.
Outcomemeasures. The primary outcomemeasureswere
the occurrence of solicited and unsolicited AEs during a 7-day
and 28-day surveillance period after each vaccination, re-
spectively. SAEs were collected throughout the study period,
which extended 24weeks after the last dose of study product.
Local solicited AEs included erythema, swelling, induration,
pain, and tenderness at the injection site. Systemic solicited
AEs included malaise, nausea, vomiting, abdominal pain,
diarrhea, fever (axillary temperature ³ 37.5C), arthralgia,
myalgia, fatigue, chills, headache, chest pain/discomfort,
shortness of breath, palpitations, and potential allergic re-
actions (wheezing, urticaria, edema/angioedema, hypoten-
sion, anaphylaxis). All solicited local AEs were considered
deﬁnitely related to the study product and solicited systemic
AEs were considered to be possibly or probably related be-
cause of existence of alternative causes.
Safety monitoring. Before being vaccinated, all volunteers
were trained to measure their body temperature using digital
thermometers. After each vaccination, the volunteers were
evaluated for solicited AEs at 15minutes, 1 hour, and 2 hours.
After 2 hours, the volunteers were transported to their homes
where study personnel collected GPS coordinates of their
houses. These were kept in the volunteers’ ﬁles to facilitate
follow-up in case of a missed scheduled visit. All volunteers
were evaluated clinically at the study center 2, 7, 14, and
28 days after each vaccination, and every 4weeks for 24weeks
after the last vaccination. In addition, study physicians called
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the volunteers by telephone on days 1, 3, 4, 5, and 6 after
each vaccination to solicit local and systemic AEs. All vol-
unteers were provided with mobile phones and encouraged
to come to the study center or call the study physician when
they felt unwell. Study physicians evaluated symptoms
identiﬁed at scheduled visits and appropriate management
was provided. In case further care was required, volunteers
were referred to appropriate services at La Paz Medical
Center where high-quality inpatient and outpatient care was
available 24 hours a day, 7 days a week. Clinical evaluations
consisted ofmeasurement of vital signs and assessment for
local injection site and general solicited signs or symptoms.
Blood for safety analyses was collected at screening, be-
fore each vaccination and on days 2, 7, 14, and 28 after
each vaccination, and every 4 weeks for 24 weeks after the
last vaccination. At screening, a complete blood count and
serum biochemistry (alanine aminotransferase [ALT ] and
aspartate aminotransferase [AST ], creatinine, bilirubin,
potassium, sodium, and alkaline phosphatase) were assessed.
At subsequent scheduled visits, a complete blood count
and limited biochemistry (ALT, AST, and creatinine) were
assessed. Biochemistry testswere performed using a Pentra
60C+ and hematological tests were done with a Roche
Cobas Integra 400 Plus.
Solicited local AEswere assessed asmild,moderate, severe,
or life threatening (grades1,2, 3, and4, respectively).Painat the
injectionsitewascategorizedasgrade1:doesnot interferewith
activity, grade2: interfereswith activity or requires repeateduse
of non-narcotic pain reliever > 24 hour, grade 3: prevents daily
activity or requires any use of narcotic pain reliever, or grade 4:
requires hospitalization. Tenderness was graded as grade 1:
mild discomfort to touch, grade 2: discomfort with movement,
grade 3: signiﬁcant discomfort at rest, or grade 4: discomfort
that requires hospitalization. Erythema, swelling, or induration
at the injection site measured at greatest single diameter were
grade 1: > 2.5–5 cm, grade 2: 5.1–10 cm, grade 3: > 10 cm, or
grade 4: presence of necrosis. Solicited systemic AEs were
assessed as mild, moderate, severe, or life threatening (grades
1, 2, 3, and 4 respectively), deﬁned as grade 1: AEs that were
easily tolerated; grade 2: AEs that interfered with daily activity,
grade 3: AEs that prevented daily activity, or grade 4: AEs that
required hospitalization.
The degree to which an AE could be attributed to vaccina-
tion was determined by the principal investigator (PI) with
advice from the rest of the clinical team and categorized as
not, unlikely, possibly, probably, or deﬁnitely related. For the
ﬁnal analysis categories, “not related” and “unlikely related”
were combined into “unrelated.” “Possibly related,” “probably
related,” and “deﬁnitely related”were combined into “related.”
Abnormal laboratory ﬁndings were graded using an FDA-
recommended14 grading scheme adapted to be consistent
with normal ranges in EG, Mali, and Tanzania. Abnormal lab-
oratory tests were assessed as clinically signiﬁcant if they
were associated with clinical symptoms or required medical
intervention or clinically nonsigniﬁcant if there were no asso-
ciated symptoms, and they required no treatment. Information
on any other symptoms, the use of any medications (pre-
scription and/or over the counter), unscheduled medical
consultations, and hospitalizations were also collected. All
aspects of the trial were assessed by a sponsor-appointed
clinical trial monitor, who also reviewed established safety
stopping criteria together with the PI.
Immunogenicity assessment. Antibody responses were
measured on sera obtained from participants before the ﬁrst
vaccination and 2 weeks after the last vaccination.
IgG antibodies to P. falciparum circumsporozoite protein
(PfCSP) by enzyme-linked immunosorbent assay (ELISA).
Antibodies against PfCSP were measured by ELISA at
Sanaria Inc. Brieﬂy, 96-well plates (Thermo Fisher Scientiﬁc,
Rochester, NY) were coated overnight at 4Cwith 2.0 μg/mL
per well of recombinant PfCSP in 50 μL coating buffer (KPL -
Sera Care, Milford,MA). Plateswere washed three times with
2 mM imidazole, 160 mM NaCl, 0.02% Tween 20, 0.5 mM
EDTA, and then blocked with 1% bovine serum albumin
(BSA), blocking buffer (KPL - Sera Care, Milford, MA) con-
taining 1%nonfat dry milk for 1 hour at 37C. The plates were
washed three times and serially diluted serum samples (in
triplicates) were added and incubated at 37C for 1 hour.
After three washes, peroxidase-labeled goat antihuman IgG
(KPL - Sera Care, Milford, MA) was added at a dilution of
0.1 μg/mL and incubated at 37C for 1 hour. Plates were
washed three times, ABTS peroxidase substrate was added
for plate development, and the plates were incubated for
75 minutes at 22C. The plates were read with a Spectramax
Plus384 microplate reader (Molecular Devices, Sunnyvale,
CA) at 405 nm. The data were collected using Softmax Pro
GXPv5 and ﬁt to a 4-parameter logistic curve, to calculate the
serum dilution at OD 1.0. A negative control (pooled serum
from non-immune individuals from a malaria free area) was
included in all assays. The positive control was pooled hu-
man sera taken 2 weeks after the last immunization from 12
volunteers immunized four or ﬁve times with PfSPZ Vaccine
in the VRC 312 clinical trial, who did not develop parasitemia
after CHMI.6 Samples were considered positive if the differ-
ence between the post-immunization OD 1.0 and the pre-
immunization OD 1.0 (net OD 1.0) was ³ 50, and the ratio of
post-immunization OD 1.0 to pre-immunization OD 1.0
was ³ 3.
IgG antibodies to PfSPZ by automated immunoﬂuores-
cence assay (aIFA). In the PfSPZ aIFA, the serum dilution at
which the arbitrary ﬂuorescence units (AFU) was 2 × 105 was
determined at Sanaria. Puriﬁed PfSPZ (NF54 strain) from
aseptic Anopheles stephensi mosquitoes produced by
Sanaria were resuspended in PBS (pH 7.4). Forty microliters
containing 0.5 × 104 PfSPZwere added to eachwell of Greiner
cellstar clear bottom black 96-well plates (Greiner Bio-One
GmbH, Frickenhausen, Germany), the plates were then left at
ambient temperature for 12–18 hour to air-dry. Two-fold serial
dilutions (50 μL/well) of sera, starting at 1:50, diluted in PBS
with 2% BSA were added to each well of the 96-well plate
containing air-dried PfSPZ and incubated at 37C for 1 hour.
The plateswerewashed in PBS three times using anAquamax
Microplate washer. Alexa Fluor 488–conjugated goat antihu-
man IgG (Life Technologies Corporation, Eugene, OR) was
diluted 1:250 in PBS with 2% BSA, and 40 μL were added to
each well. The plates were then incubated for 1 hour at 37C,
washed three times with PBS, and then 100 μL PBS was
added to eachwell. Theplateswere sealedusing aplate sealer
and stored in the dark at 4C until data acquisition. Samples
were assessed by scanning the plates using an Acumen eX3
laser scanning imaging cytometer. The positive control was
the same pooled human sera used for ELISA. The Acumen
image cytometer scans the entire surface area of eachwell in a
96-well plate, and the ﬂuorescence intensity values (arbitrary
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units) therefore represent the signal from all 0.5 × 104 PfSPZ
that were seeded in each well.
Data were plotted to ﬁt a 4-parameter sigmoid curve
in GraphPad Prism software using serum dilution (log trans-
formed) as the xaxis variable andAFUon the yaxis.Overmany
iterations during development of this assay, we have de-
termined that sera from naı¨ve volunteers in the United States
and Europe, including pre-immune sera, always register an
arbitrary ﬂuorescence value less than 2.0 × 105 even at
the highest concentration (1:50 dilution) used in this assay.
Moreover, sera that do react toPfSPZ, 2.0 ×105AFU, fall in the
exponential portion of their sigmoidal curves. Therefore, 2.0 ×
105 has been chosen as a threshold in the aIFA assay, and the
results for each volunteer for antibodies to PfSPZ are reported
as the reciprocal serum dilution at which ﬂuorescence in-
tensity was equal to 2.0 × 105 AFU. For this study, the AFU
values were calculated for sera collected before immunization
and after immunization because individuals pre-exposed to
malaria in EG were expected to harbor antibodies to PfSPZs
before immunization with PfSPZ Vaccine. Sera were consid-
ered positive for seroconversion if their net AFU 2 × 105 and
AFU 2 × 105 ratio, calculated respectively by subtracting the
pre-vaccination from the post-vaccination AFU 2 × 105 and
dividing the post-vaccination by the pre-vaccination AFU 2 ×
105 were ³ 150 and ³ 3.0, respectively.
Functional antibodies to PfSPZ by inhibition of sporozoite
invasion (ISI) assay. HC-04 (1F9) cells (hepatocytes) were
cultured in complete medium (10% FBS in DMEM/F12 with
100 units/mLpenicillin and 100 μg/mL streptomycin; Gibco by
Life Technologies, Grand Island, NY) in (Entactin-Collagen
IV-Laminin) ECL-coated96-well clear bottomblackwell plates
(Greiner Bio-One GmbH, Frickenhausen, Germany) at a den-
sity of 2.5 × 104 cells per well, and incubated for 24 hours at
37C, 5%CO2 with 85% relative humidity. Twenty-four hours
later, cells were infected with 104 aseptic, puriﬁed, cry-
opreserved PfSPZ per well, without or with sera diluted in an
11-point dilution series from subjects immunized with PfSPZ
Vaccine. The assay control included PfSPZ added with media
alone. Sera were assessed at pre-immunization (baseline)
and predetermined time points after immunization. PfSPZ
that had not invaded the HC-04 cells were removed 3 hours
later by washing three times with Dulbecco’s phosphate-
buffered saline, and the cultures were ﬁxed using 4%
paraformaldehyde for 15 minutes at room temperature.
Differential immunostaining was performed to distinguish
between PfSPZ inside the hepatocytes versus PfSPZ out-
side the hepatocytes. PfSPZ outside the hepatocytes were
stained with an anti-PfCSP mAb (2A10, 6.86 μg/mL) (Protein
Potential LLC, with permission from New York University
School ofMedicine) conjugatedwith Alexa Fluor 633 (far-red)
(1 μg/mL; custom-conjugated at GenScript® USA Inc., Pis-
cataway, NJ), a 1:500 dilution. The hepatocytes were then
permeabilizedwith 0.1%Triton X-100 for 15minutes at room
temperature, and the PfSPZ inside the hepatocytes were
stained with the anti-PfCSP mAb (2A10, 6.86 μg/mL) con-
jugated with Alexa Fluor 488 (green; 1 μg/mL, conjugated
from Genscript USA Inc., Piscataway, NJ), a 1:500 dilution.
The numbers and intensity of infected hepatocytes (green
only) were counted by scanning the plates using an Acumen
eX3 laser scanning imaging cytometer. Inhibitory activity at
each serum dilution sera was calculated using the following
formula:
FIGURE 1. Consort diagram for EGSPZV1 clinical trial.
Percent inhibition¼ 100

Fluorescence values of invadedPfSPZ in presence of serum*100
Fluorescence values of invadedPfSPZ inmedia control

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The number of invaded PfSPZ scored in this assay in the ab-
sence of serum was 400–600, giving an intensity of 1–3 × 106
ﬂuorescence units. Data were plotted to ﬁt a 4-parameter sig-
moidcurve inGraphPadPrismsoftware using serumdilution (log
transformed) as the x axis variable and percent inhibition on the
y axis. Eighty percent inhibition was interpolated from the sig-
moidal curves as the reciprocal serum dilution at which the
ﬂuorescence intensity of infected wells with serumwas 20%of
the negative control without serum. The serumdilution atwhich
inhibition of PfSPZ invasion into hepatocytes was 80% as
compared with a negative control without serum was desig-
nated as ISI activity. Sera with a net ISI activity of ³ 10% be-
tween post- and pre-immunization sera and a ratio of post- to
pre-vaccination ISI activity of ³ 3.0 were considered positive.
Statistical analysis. This was a phase 1 clinical trial with no
formal sample size calculation. We compared the proportion
of subjects with AEs as well as frequencies of individual AEs
between vaccination groups recorded from the ﬁrst vaccina-
tion through study conclusion (24 weeks post last vaccination).
The data for local and systemic AEs were grouped by vac-
cination groups and summarized by frequency and severity
of AEs using descriptive statistics. A two-sided Fisher’s exact
test was used to compare the frequency of AEs between
vaccinees and controls. For the immunogenicity analysis,
change from thebaselineof anti-PfCSPantibodieswasplotted
by vaccine group and time points together with the median
and interquartile ranges. Nonparametric statistics (Wilcoxon–
Mann–Whitney test) were used to compare the change of
PfSPZantibody from thebaseline betweenPfSPZVaccine and
NS groups. The Spearman correlation coefﬁcient was used to
assess the association between the results of the different
antibody assays. Fixed effect regression model was used to
TABLE 1
Demographic and baseline characteristics by group of study population
Group 1 PfSPZ Vaccine Group 2 PfSPZ Vaccine Group 3 normal saline
Number of volunteers 3 20 10
Mean age (range) 19.7 (19–20) 20.0 (17–26) 22.9 (18–33)
Mean body mass index (range) 22.5 (20.6–24.8) 23.0 (18.8–28.6) 22.1 (19.5–24.0)
PfSPZ = Plasmodium falciparum sporozoites.
FIGURE 2. Comparison of adverse events (AEs) in volunteers receiving normal saline (NS) and PfSPZ Vaccine. The percent of volunteers with a
speciﬁc AE is depicted. Only a single volunteer had any individual AE after each immunization (maximum of 1/10 [10%] for NS and 1/20 [5%] for
PfSPZ Vaccine). U, V, £, β are individual volunteers. This ﬁgure appears in color at www.ajtmh.org.
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evaluate the effect of PfSPZ Vaccine on hematology (white
blood cells [WBCs], neutrophils, and eosinophils) parameters
taking into account the repeated measurements in each vol-
unteer over time. Data were analyzed using STATA 13.0. Anti-
PfCSP antibody activities were compared between different
clinical trials using a Kruskal–Wallis test followed by a Dunn’s
multiple comparisons test for signiﬁcance between pairs.
These data were analyzed using GraphPad Prism 7.
Genotyping of parasites. One volunteer developed
asymptomatic Pf infection 5 months after the third dose of
PfSPZ Vaccine. The Pf parasites from this volunteer were
assessed by microsatellite analysis15 to determine if the
parasites were derived from PfSPZ Vaccine (PfNF54) or
from a naturally acquired infection. The DNA was isolated
from a blood specimen using Quick-gDNA Blood MiniPrep
Kit (Zymo Research, Irvine, CA). Unlinked microsatellite
markers Poly alpha, PfPK2, TA81, ARA2, TA87, and TA40
were ampliﬁed using heminested PCR.15 Capillary elec-
trophoresis was performed using an Applied Biosystems
3730XL 96-capillary DNA sequencer and software. Capil-
lary electrophoresis output ﬁles were analyzed using
Geneious 8.1.8 software. The detailed protocol is avail-
able on the University of Maryland website (http://www.
medschool.umaryland.edu/malaria/Protocols/). Genomic con-
trol strains NF54, 3D7, 7G8, HB3, and V1S (ATCC-MR4, Man-
assas, VA) were included to determine characteristic peak
morphology for each microsatellite locus and control for slight
variations among runs. Peak sizes were determined bymanual
inspection of each electropherogram and then normalized
against the Genescan™ 600 Liz® size standard (Applied Bio-
systems, Foster City, CA). Normalized peak sizes were com-
pared with those observed for PfNF54.
RESULTS
Study population. Between March and April 2015, 57
adults were screened and of the 40 who met the eligibility
criteria, 33 were enrolled into the study (Figure 1). Three vol-
unteers were enrolled into Group 1, and 30 volunteers were
randomized into Groups 2 (N = 20) and 3 (N = 10). The most
common reasons for exclusion were positive HBSAg and/or
positive HIV tests. Of 57 volunteers screened, helminth in-
fections were diagnosed in 31 (54%). The mean age at en-
rollment was 20 (17–26) years in the PfSPZ Vaccine group and
23 (18–33) years in the control group. All the groups were
generally similar at enrollment with regard to age and body
mass index (Table 1). Of the 33 volunteers, all received all
scheduled immunizations, and 31 (94%) completed all follow-
up visits. Two volunteers failed to complete their follow-up;
one vaccinee traveled abroad for further studies 2 months
after the last vaccination, and one control was lost to follow up
at 5months after the last vaccination. The two volunteerswere
healthy at their last scheduled visits.
Vaccine administration. Vaccinations took place over a
4-month period from March through August 2015. Study
nurses administered the vaccine by DVI. Injection by DVI was
completed in one attempt in 88 of 96 (92%) administrations.
The other eight administrations were completed in two at-
tempts. The nurse performing the injection judged the pro-
cedure as simple in 87 of the 88 (99%) single-attempt
injections. Of 96 administrations, 91 (95%) were judged to be
painless by the volunteers, and ﬁve (5%) were judged to be
associated with mild pain. The entire DVI procedure from the
time of syringe handover to completion of injection took a
mean of 3.80 (1–8) minutes, 2.19 (1–5) minutes, and 2.40 (1–5)
minutes in the safety sentinel, PfSPZ Vaccine, andNS groups,
respectively.
Solicited and unsolicited AEs. No volunteer developed
local or systemic solicited AEs in the sentinel group of three
volunteers who received two vaccinations with PfSPZ Vac-
cine. No local solicited AEs were reported after administration
of any of the three doses of PfSPZ Vaccine and NS in themain
groups. Overall, three of 20 (15%) and one of 10 (10%) vol-
unteers reported a systemic solicited AE after any of the three
doses in the PfSPZ Vaccine and NS groups, respectively
(Figure 2). Of the 11 reported systemic AEs, nine (82%) were
grade 1, and 2 (18%) were grade 2 (one in the PfSPZ Vaccine
and one in the NS group) (Figure 2). All solicited AEs resolved
without sequelaewithin 7days after vaccination. Therewasno
TABLE 2
Number of solicited AEs after an injection in recipients of NS and
PfSPZ Vaccine
AE NS N (%)*
PfSPZ Vaccine
N (%)*
Local (site of injection)
Any AE 0 0
Systemic
Headache 1 (3%) 2 (3%)
Abdominal pain 0 2 (3%)
Chills 0 1 (2%)
Diarrhea 0 1 (2%)
Vomiting 0 1 (2%)
Arthralgia 1 (3%) 0
Fever 1 (3%) 1 (2%)
Myalgia 0 0
Allergic reactions 0 0
Chest pain/palpitations/shortness of
breath
0 0
TOTAL 3 (10%) 8 (13%)
AE = adverse event; N = number of AEs; NS = normal saline; PfSPZ = Plasmodium
falciparum sporozoites.
% = Percentage of injections which gave rise to the AE using number of injections (60
injections for vaccine group, 30 injections for NS group) as denominator. There were no
signiﬁcant differences in the incidence of solicited AEs between recipients of NS and PfSPZ
Vaccine.
* The P value for the Fisher exact test (2-sided) comparing the two groups for each AE and
overall AE rate was > 0.05 for all comparisons.
TABLE 3
Number of unsolicited AEs in recipients of NS and PfSPZ Vaccine
Unsolicited AEs (MedRA term) NS N (%)*
PfSPZ Vaccine
N (%)*
Dental and periodontal infections 1 (6.3%) 3 (18.8%)
Ear and labyrinth disorders 0 (0.0%) 1 (6.3%)
Gastrointestinal disorders 0 (0.0%) 1 (6.3%)
General disorders 3 (18.8%) 1 (6.3%)
Infections and infestations 6 (37.5%) 8 (50.0%)
Injury and procedural complications 2 (12.5%) 0 (0.0%)
Musculoskeletal and connective tissue
disorders
3 (18.8%) 1 (6.3%)
Nervous system disorders 0 (0.0%) 1 (6.3%)
Skin and subcutaneous tissue disorders 1 (6.3%) 0 (0.0%)
Total number of unsolicited AEs 16 16
AE = adverse event; NS = normal saline; PfSPZ = Plasmodium falciparum sporozoites.
There were no signiﬁcant differences in the incidence of unsolicited AEs between recipients
of NS andPfSPZ Vaccine. TheP valueswere calculated on a per volunteer basis (e.g. 3/20 vs.
1/10 for dental and periodontal infections) in a two-sided Fisher’s exact test. All P values
were ³ 0.1.
* The numbers in brackets are calculated as the proportion of the total unsolicited AEs
reported.
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evidence of increasing frequency or severity of reported local
and/or systemic solicited AEs with subsequent doses of
vaccine nor were there reports of anaphylaxis or any other
serious allergic reactions. There was no signiﬁcant difference
in the frequency of solicited AEs between PfSPZ Vaccine and
NS groups (Table 2).
There were 32 unsolicited AEs reported during the study, of
which 27 (84.4%) were mild (grade 1), three (9.4%) were
moderate (grade 2), and two (6.2%) were of severe (grade 3)
severity (Table 3). The two severe unsolicited AEs were perio-
dontitis and toothache. One volunteer completed treatment
of periodontitis and recovered within 16 days. The other vol-
unteer’s severe toothache resolved after 2 days. Subsequent
evaluation revealed that he had pre-existing dental caries.
None of the unsolicited AEs were considered related to the
Investigational Product. All other unsolicited AEs resolved
without sequelae. There was no statistically signiﬁcant dif-
ference in frequency of unsolicited AEs between volunteers
receiving PfSPZ Vaccine and those receiving NS (P = 0.319,
Fisher’s exact test, 2-tailed) (Table 3).
One volunteer developed asymptomatic Pf infection
5 months after the third dose of PfSPZ Vaccine. The volun-
teer was treated with artesunate–amodiaquine, and a repeat
blood smear 7 days later conﬁrmed clearance of para-
sitemia. The microsatellite patterns of the DNA from the
parasites from this individual indicated that the volunteer
was not infected with PfNF54, the Pf strain used to make
PfSPZ Vaccine. The microsatellite analysis indicated that
the volunteer was infected with multiple other strains of Pf.
Overall, no unexpected or SAEs occurred. Furthermore, no
volunteers were withdrawn because of AEs.
Laboratory safety tests. Most of the abnormal hematol-
ogy (WBC and differentials) and biochemistry (serum creati-
nine, ALT and AST) laboratory abnormalities were grade
1 and 2 (Table 4). Eosinophilia was a common laboratory
abnormality, occurring at some point in most volunteers
and often associated with the presence of helminth infec-
tions, which includedAscaris lumbricoides, Trichuris trichiura,
and Schistosoma haematobium. The only grade 3 laboratory
abnormality identiﬁed after vaccination in the main study
groups, an elevated eosinophil count in a PfSPZ Vaccine re-
cipient, was associated with infection with S. haematobium,
and fell to grade 1 after treatment. Transient, grade 1–2 de-
creases in neutrophil counts were also common, but showed
no relationship to administration of PfSPZ Vaccine, occurring
more frequently in control volunteers than vaccine recipients.
Eosinophils and WBCs had a minimal, but signiﬁcant down-
ward trend during the study period in the PfSPZ Vaccine
group, but not in NS controls (data not shown). Elevated ALT
and AST levels, which could theoretically be expected after
the administration of a live PfSPZ vaccine, occurred with
similar frequency in vaccine and control volunteers. In sum-
mary, there were no signiﬁcant trends or group differences in
laboratory parameters indicating a vaccine effect.
Immunogenicity. In the PfCSP ELISA, 14/20 (70%) of
vaccinated subjects and 0/10 (0%) of control subjects
were considered to have become positive as compared
with before immunization (P = 0.0003, Fisher’s exact test,
2-tailed) with a median net OD 1.0 of positives of 890 and
the median OD 1.0 ratio of positives of 9.50 (Table 5).
Among positives, the net OD 1.0 ranged from 136 to 2,414,
and the OD 1.0 ratio ranged from 3.10 to 23.66 (Figure 3A)
( Table 5).
In the aIFA, 13/20 (65%) of vaccinated subjects and 3/10
(30%) of control subjects were considered to have become
positive as compared with before immunization (Figure 3B)
(Table 5) (P=0.12). Amongpositive vaccinees, the net AFU2×
105 ranged from 150 to 647, and the AFU 2 × 105 ratio ranged
from 3.10 to 270 (Table 5). Of the 14 vaccinees who sero-
converted by PfCSP ELISA, only one did not seroconvert by
PfSPZ aIFA (Table 5).
In the ISI, 9/20 vaccinees and 1/10 control subjects were
considered to have become positive as compared with before
immunization (Figure 3C) (Table 5) (P=0.10). All ninewere also
positive by PfCSP ELISA, and 8/9 were positive by the aIFA.
Among positives, the net ISI activity ranged from 11.42 to
63.23 and the ISI activity ratio ranged from 3.14 to 25.63
(Table 5).
TABLE 4
Laboratory abnormalities
Laboratory parameter* Grade abnormality Pilot N (%) PfSPZ Vaccine N (%) Normal saline N (%)
Decreased hemoglobin 1 0 (0%) 0 (0%) 1 (10%)
Decreased platelets 1 0 (0%) 4 (20%) 0 (0%)
Increased WBC count 1 0 (0%) 5 (25%) 2 (20%)
2 – – 1 (5%) – –
Decreased WBC count 1 1 (33%) 5 (25%) 5 (50%
Decreased neutrophils 1 1 (33%) 17 (85%) 8 (80%)
2 – – 1 (5%) 2 (20%)
Decreased lymphocytes 1 1 (33%) 0 (0%) 1 (10%)
Increased eosinophils 1 0 (0%) 14 (70%) 10 (100%)
2 – – 11 (55%) 3 (30%)
3 – – 1 (5%) – –
Elevated ALT 1 1 (33%) 8 (40%) 4 (40%)
Elevated AST 1 0 (0%) 6 (30%) 3 (30%)
2 – – 2 (10%) – –
Elevated total bilirubin 1 0 (0%) 0 (0%) 0 (0%)
Elevated creatinine 1 1 (33%) 0 (0%) 2 (20%)
Hypoglycemia 1 0 (0%) 2 (10%) 0 (0%)
Hyperglycemia 1 1 (33%) 2 (10%) 1 (10%)
2 1 (33%) – – 1 (10%)
ALT=alanine aminotransferase;AST=aspartate aminotransferase; N=number of volunteers experiencing the abnormality; PfSPZ=Plasmodium falciparum sporozoites;WBC=white bloodcell;
% = proportion of the number of volunteers in the group experiencing the abnormality. Number (percent) of volunteers experiencing laboratory abnormalities after vaccination (excluding
abnormalities identiﬁed at screening or prior to the ﬁrst vaccination).
* Abnormal Laboratory Values are deﬁned as grade 1 or higher per the protocol deﬁned toxicity ranges.
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The antibody responses by ELISA (net OD 1.0) and net
ISI activity (80% inhibition of PfSPZ invasion) were posi-
tively correlated 2 weeks after the third dose (r2 = 0.39, P =
0.0033); the samewas true for correlation betweenPfCSPELISA
and net aIFA (r2 = 0.52, P = 0.0003). There was no signiﬁcant
correlation between net aIFA and net ISI (r2 = 0.11, P = 0.16).
We compared the anti-PfCSP responses by ELISA at
2 weeks (United States, Mali, EG) or 4 weeks (Tanzania)
after administration of three doses at 8-week intervals of
2.7 × 105 PfSPZ to adults in EG, to responses to three doses
of 2.7 × 105 PfSPZ administered to adults at 4-week intervals
in Mali7 and Tanzania (Jongo, unpublished data), and in the
United States at 4-week intervals or over 20 weeks8,9
(Figure 4). Responseswere signiﬁcantly lower inMali and EG
than in the United States, and the responses in EG were
signiﬁcantly lower than in Tanzanian young adults who had
minimal exposure to malaria during the previous 5 years.
There was no difference in responses in sera from Mali
and EG.
DISCUSSION
We have conducted the ﬁrst clinical trial in the history of
EG. There were signiﬁcant regulatory, quality, clinical, and
logistical challenges in conducting this trial fully adhering to
the international standards of Good Clinical Practices. A
detailed report of these developments and capacity build-
ing efforts will be published elsewhere. The trial was suc-
cessful in showing that three doses of 2.7 × 105 PfSPZ of
PfSPZ Vaccine were safe, well tolerated, and moderately
immunogenic in healthy 18–35-year-old male Equatogui-
neans living in an area with low malaria exposure.
Almost all the vaccinees and controls indicated that there
was no pain associated with injection of PfSPZ Vaccine by
DVI. There were no differences in the rate of solicited or un-
solicited AEs between the 20 volunteers who received PfSPZ
Vaccine and the 10 who received NS. There were no local
solicited AEs or severe solicited systemic AEs after vaccina-
tion, and only two grade 3 unsolicited AEs were reported
during the trial, both unrelated to investigational product. We
observed no unexpected trends in hematological (hemoglobin,
hematocrit, WBCs, platelets) or biochemical (creatinine, ALT,
AST) laboratorymarkersexcept that eosinophils andWBCshad
a minimal, but signiﬁcant downward trend during the study
period in the PfSPZ Vaccine group, but not in NS controls. We
havenoexplanation for thisﬁnding. Theexcellent reactogenicity
and safety proﬁle in Equatoguineans immunized with PfSPZ
Vaccine is consistent with ﬁndings from Mali7 and Tanzania
TABLE 5
Immune responses in volunteers receiving NS and PfSPZ Vaccine before the ﬁrst immunization and 2 weeks after the third immunization
Group Volunteer ID
ELISA PfCSP OD 1.0 aIFA AFU 2 × 105 ISI reciprocal serum dilution for 80% inhibition
Pre-immune* Immune† Net‡ Ratio§ Pre-immune* Immune† Net‡ Ratio§ Pre-immune* Immune† Net‡ Ratio§
NS 201 188 342 154 1.82 0 73 73 73.00 4.91 21.33 16.41 4.34
222 192 278 86 1.45 0 71 71 71.00 15.31 16.31 0.99 1.06
225 38 37 −1 0.97 73 345 272 4.73 13.72 2.60 −11.13 0.19
232 102 158 56 1.55 54 81 27 1.50 0.00 8.83 8.83 8.83
235 62 158 96 2.55 127 216 89 1.70 13.76 14.11 0.36 1.03
241 167 133 −34 0.80 0 39 39 39.00 9.36 12.88 3.52 1.38
251 654 481 −173 0.74 138 0 −138 0.00 17.43 3.75 −13.69 0.21
253 45 47 2 1.04 19 104 85 5.47 10.17 21.02 10.84 2.07
256 95 210 115 2.21 0 238 238 238.00 13.15 25.61 12.46 1.95
258 39 40 1 1.03 0 372 372 372.00 7.31 7.55 0.23 1.03
Median 99 158 29 1.25 19 93 79 22.24 11.66 13.50 2.26 1.22
PfSPZ Vaccine 203 46 808 762 17.57 0 270 270 270.00 0.00 9.93 9.93 9.93
204 328 551 223 1.68 134 122 −12 0.91 12.51 28.69 16.18 2.29
206 275 412 137 1.50 212 268 56 1.26 16.05 5.75 −10.29 0.36
212 172 1,472 1,300 8.56 18 252 234 14.00 8.60 67.53 58.93 7.85
215 77 603 526 7.83 88 488 400 5.55 0.00 14.06 14.06 14.06
217 85 938 853 11.04 74 470 396 6.35 4.55 20.71 16.15 4.55
218 89 736 647 8.27 82 254 172 3.10 13.55 31.99 18.44 2.36
226 311 381 70 1.23 259 340 81 1.31 5.65 2.44 −3.22 0.43
227 525 536 11 1.02 417 293 −124 0.70 12.67 27.71 15.04 2.19
229 237 1,314 1,077 5.54 127 538 411 4.24 21.80 33.79 11.99 1.55
231 118 1,547 1,429 13.11 84 404 320 4.81 0.00 39.64 39.64 39.64
233 199 1,472 1,273 7.40 59 706 647 11.97 0.00 20.32 20.32 20.32
236 62 198 136 3.19 299 292 −7 0.98 3.07 20.03 16.96 6.52
242 47 755 708 16.06 16 341 325 21.31 21.38 39.39 18.01 1.84
243 188 1,115 927 5.93 0 329 329 329.00 15.27 5.53 −9.74 0.36
244 23 240 217 10.43 0 151 151 151.00 0.00 11.18 11.18 11.18
249 106 219 113 2.07 71 147 76 2.07 10.95 18.46 7.51 1.69
250 47 1,112 1,065 23.66 3 512 509 170.67 21.35 46.07 24.72 2.16
252 236 2,650 2,414 11.23 44 272 228 6.18 8.13 27.76 19.63 3.41
257 42 90 48 2.14 45 107 62 2.38 22.56 19.12 −3.43 0.85
Median 112 746 678 7.61 72 292 231 5.18 9.77 20.51 15.60 2.33
AFU= arbitrary ﬂuorescence units; aIFA= automated immunoﬂuorescence assay; ELISA =enzyme-linked immunosorbent assay; ISI = inhibition of sporozoite invasion assay;NS= normal saline;
PfCSP=Plasmodium falciparum circumsporozoite protein; PfSPZ =P. falciparum sporozoites; Volunteer ID = volunteer identiﬁcation number. Immune responsesweremeasured in all Group 2 and
Group 3 volunteers using PfCSP ELISA, aIFA, and ISI assays. Those in bold were considered to have developed antibodies after immunization.
* Pre-immune sera taken before the ﬁrst immunization.
† Immune sera taken 2 weeks after the last immunization.
‡Net = immune–pre-immune value.
§Ratio = immune/pre-immune value. All values of 0 were changed to 1 when calculating ratios.
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(Jongo et al., unpublished data) where similar doses of
PfSPZ Vaccine were administered. Higher doses of PfSPZ
Vaccine are currently being assessed in infants, children,
and adults in EG.
The tolerability and safety proﬁles are also consistent with
results of multiple other studies of PfSPZ Vaccine,6–10,13
PfSPZ Challenge (live PfSPZ for infection),16–19 and PfSPZ-
CVac (PfSPZ Challenge with an antimalarial drug).20,21 So far,
no breakthrough malaria infections have been observed with
Sanaria’s radiation-attenuated PfSPZ Vaccine. There was no
evidence for local or severe systemicAEs, thought tobedue to
the quality (e.g., purity and sterility) of PfSPZ Vaccine. This
favorable safety and tolerability proﬁle will facilitate compli-
ance if PfSPZ Vaccine is used, as planned,22,23 in mass vac-
cination programs.
PfSPZ Vaccine induced antibody responses to PfCSP and
PfSPZ.However, induction of functional activity assessed by
ISI was modest. The antibody responses in this EG study
were signiﬁcantly lower than in a U.S. study in which the
same immunization regimen was administered, but similar to
antibody responses in a study in a highly endemic area of
Mali (Figure 4). Interestingly, antibody responses were higher
in young adult Tanzanians who were selected for having
had minimal exposure to malaria during the past 5 years
(Figure 4). We hypothesize that long-term exposure to Pf
infections leads to downregulation of immune responses to
PfSPZ Vaccine. It is also possible that an activated immune
microenvironment, compared with that in Americans, re-
duced the antibody responses. This has been shown for a
yellow fever vaccine study in Entebbe, Uganda.24 Additional
studies will be needed to better explain and overcome this
poor immunogenicity.
The baseline rate of helminth infection (54%) was high. The
most common helminths were A. lumbricoides, T. trichiura
andS. haematobium. Helminth infection can impair responses
to vaccines against various diseases,25–27 and speciﬁcally
impaired antibody responses after vaccination with subunit
malaria vaccines inhumans28andmice.29,30 Incontrast, helminth
infection did not affect the immunogenicity and protection of
radiation-attenuated SPZ vaccine inmice.31 The helminth rate at
enrollment was signiﬁcantly lower in Mali (3/93 (3.2%)7 where
antibody responses were similarly low (Figure 4). Thus, we do
not think that active, ongoing helminth infections alone were
responsible for the poor antibody responses. Nonetheless, we
will continue to study the impact of helminth infections on im-
munogenicity and protective efﬁcacy where possible.
Trained study nurses performed all of the DVI injections of
PfSPZ Vaccine and NS. The procedure took little time to learn
or to perform and was largely painless. At the time of writing
this manuscript, > 4,000 injections by DVI of PfSPZ Vaccine,
PfSPZ-CVac,20,21 PfSPZ Challenge,16–19 or NS placebo have
been administered to > 1,900 individuals worldwide, including
infants and children in Tanzania, Kenya, and EG. It is more
challenging to administer by DVI to children less than 2 years
of age than to older children, adolescents, and adults. How-
ever, experience from studies conducted inMali and Tanzania
shows that injection skills improve signiﬁcantly with practice,
and more than 350 5–12-month-old infants have successfully
received PfSPZ Vaccine or NS placebo by DVI. Data from an
ongoing PfSPZ Vaccine study in Kenya including more than
300 infants will provide even more insight into the operational
requirements for DVI in young children and infants.
In conclusion, PfSPZ Vaccine was safe and well tolerated in
young Equatoguinean adults living in an area of low malaria
transmission, but the vaccine induced lower anti-PfCSP an-
tibody responses compared with those in malaria-naı¨ve
adults. Further studies are ongoing to improve the immuno-
genicity through dose escalation. By successfully conducting
the ﬁrst clinical trial in the country’s history, we have laid
the foundation for development of a robust research and
FIGURE 3. Antibody responses 2 weeks after the last vaccination. Responses in all vaccinees and controls who received three doses of PfSPZ
Vaccineor normal salineweremeasuredby (A)Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP) enzyme-linked immunosorbent assay
(ELISA), (B) Automated immunoﬂuorescence assay (aIFA), and (C) Inhibition of sporozoite invasion assay (ISI) assay. In the ELISA, antibody
responses are reportedas thenetOD1.0.OD1.0 is the serumdilutionatwhich theoptical density is 1.0, andnetOD1.0 is the differencebetween the
post- and pre-immunization OD 1.0. In the aIFA assay, antibody responses are reported as the reciprocal serum dilution at which the arbitrary
ﬂuorescence units (AFU) were 2 × 105. In the ISI assay, antibody responses are reported as the reciprocal serumdilution that gave 80% inhibition of
PfSPZ invasion. Medians with interquartile ranges are shown.
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development program in EG that will contribute to future
malaria elimination efforts.
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